Experience

Systems Oncology

• United States
• Biotechnology Research
• 1 - 100 Employee

• Senior Scientist, Oligonucleotide Chemistry

  • Nov 2021 - Present

  • Established synthetic oligonucleotide chemistry within the company • Designs, synthesizes (LGC MerMade 12 synthesizer) and purifies RNA as cancer therapeutics, including siRNA and aptamers • Sourced, operates and maintains a QTOF LC-MS for the analysis of oligonucleotides, including target confirmation, impurity identification and QC work • Sourced, operates and maintains a preparative HPLC for the purification of oligonucleotides • Established synthetic oligonucleotide chemistry within the company • Designs, synthesizes (LGC MerMade 12 synthesizer) and purifies RNA as cancer therapeutics, including siRNA and aptamers • Sourced, operates and maintains a QTOF LC-MS for the analysis of oligonucleotides, including target confirmation, impurity identification and QC work • Sourced, operates and maintains a preparative HPLC for the purification of oligonucleotides



University of Arizona

• United States
• Higher Education
• 700 & Above Employee

• Researcher / Scientist III

  • Oct 2020 - Nov 2021

  Principal Investigator: Dr. Timothy MarloweUA College of Medicine -- Phoenix, Department of Internal MedicineThis is a continuation of my position at UA, but with a change of affiliation to the COM-PHX Dept. of Internal Medicine.

• Assistant Research Scientist

  • Feb 2018 - Oct 2020

  Principal Investigators: Drs. Timothy Marlowe and William CanceUniversity of Arizona Cancer Center• Established medicinal / synthetic chemistry within the group• Leads the chemistry efforts to create novel focal adhesion kinase (FAK) scaffold inhibitors through structure based drug design (SBDD), fragment based drug design (FBDD), microwave-assisted solid phase peptide synthesis (SPPS) and traditional medicinal chemistry approaches• Manages B.S. / M.S. researchers• Contributes to grant writing, budgeting, purchasing, hiring, etc. Show less



Northeastern University

• United States
• Higher Education
• 700 & Above Employee

• Affiliated Research Associate Professor

  • May 2017 - May 2018

• Senior Research Scientist

  • Nov 2015 - May 2017

  Laboratory for Neglected Tropical Infectious Diseases, Northeastern University, Boston, MAPrincipal Investigator: Professor Michael P. Pollastri• Lead the in-house chemistry efforts on a structure-based drug design project targeting dihydrofolate reductase (DHFR) as found in Mycobacterium tuberculosis• Managed three Ph.D.-level researchers• Mentored one undergraduate researcher• Worked with external collaborators including biochemists, molecular modelers, in vivo biologists and contract laboratory personnel• Contributed to NIH grant writing• Helped manage the project budget• Designed and synthesized an alkyne tagged analog of disulfiram• As an experienced chemist, actively contributed to chemistry discussions and problem solving within the research group Show less



VioGen Biosciences

• Greater Salt Lake City Area

• Senior Scientist

  • Oct 2014 - Jun 2015

  • Contract medicinal chemistry • Synthesis of isotopically labeled and unlabeled reference standards • Contract medicinal chemistry • Synthesis of isotopically labeled and unlabeled reference standards



Bioconjugate Technologies (aka Click Chemistry Tools)

• Scottsdale, AZ

• Senior Scientist

  • Jan 2014 - Jun 2014

  • Design and synthesis of novel bioconjugate entities • Synthesis of existing products • Typically worked on 20 – 50 g scale reactions • Design and synthesis of novel bioconjugate entities • Synthesis of existing products • Typically worked on 20 – 50 g scale reactions



The University of Kansas

• United States
• Higher Education
• 700 & Above Employee

• Staff Scientist

  • Oct 2009 - Jan 2014

  The University of Kansas Specialized Chemistry Center was part of the Molecular Libraries Probe Production Centers Network. The nine centers of the MLPCN carried out high-throughput screening and hit-to-lead medicinal chemical optimization dedicated to the discovery of new small molecules for biomedical research. Principal Investigator and Director: Professor Jeffrey Aubé • Hit to lead optimization of HTS hits • I have worked in the therapeutic areas of antibacterials (tuberculosis and cholera), antiparasitics (trypanosomiasis and malaria), MDR pump inhibition, cancer and CNS • Contributed to project planning, patents and publications Show less



Myriad Genetics

• United States
• Biotechnology Research
• 700 & Above Employee

• Scientist II

  • Feb 2002 - Feb 2009

  • Helped direct Chemistry team on a cancer project • Designed, synthesized and developed structure-activity relationships (SAR) for programs in anticancer, antiviral and Alzheimer's disease • Developed methodology and prepared metabolites of tarenflurbil for preclinical studies • Provided multigram quantities of critical intermediates and final products for ongoing projects under stringent timelines (with reactions upwards of 200 g in scale) • Worked with contract research organizations (CROs) on projects that included chemistry troubleshooting and technology transfer • Contributed to patents • Managed and mentored Research Associates Show less



Astellas Pharma US

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Research Scientist

  • Jan 2001 - Jan 2002

  • Performed medicinal chemistry and scale-up on pyrimidines and pyrrolopyrimidines for an asthma project (adenosine receptor) • Performed medicinal chemistry and scale-up on pyrimidines and pyrrolopyrimidines for an asthma project (adenosine receptor)



New Mexico State University

• Higher Education
• 700 & Above Employee

• Postdoctoral Fellow

  • 1999 - 2001

  Advisor: Professor Robert V. Hoffman • I developed methodology for the substrate-controlled synthesis of enantioenriched alpha-amino halomethyl ketones and alpha-amino epoxides from alpha-amino acids Advisor: Professor Robert V. Hoffman • I developed methodology for the substrate-controlled synthesis of enantioenriched alpha-amino halomethyl ketones and alpha-amino epoxides from alpha-amino acids



University of Pittsburgh

• United States
• Higher Education
• 700 & Above Employee

• Postdoctoral Fellow

  • 1998 - 1999

  Advisor: Professor Peter Wipf • I enantioselectively synthesized a biologically active chromene derivative. My observation of photoracemization contributed to chromene chemistry and I was one of the first to utilize a ring closing methathesis approach (RCM) to this structure Advisor: Professor Peter Wipf • I enantioselectively synthesized a biologically active chromene derivative. My observation of photoracemization contributed to chromene chemistry and I was one of the first to utilize a ring closing methathesis approach (RCM) to this structure